Involvement of natural killer cells in the pathogenesis of endometriosis in patients with pelvic pain

Jue He1,#, Yan Xu1,#, Minhui Yi1,#, Cancan Gu2, Yi Zhu1 and Guohua Hu2

Abstract

Objectives: To detect the involvement of immune cells in the pathogenesis of endometriosis in patients with stable status or pelvic pain.

Methods: Blood was collected from patients with endometriosis with and without pelvic pain. Natural killer (NK) and Th17 cells were analyzed by flow cytometry, and secretion of inflammatory cytokines (tumor necrosis factor-α, interleukin (IL)-1β, IL-6, IL-7) was verified by enzyme-linked immunosorbent assay. We isolated immune cells from blood by density-gradient centrifugation to investigate the expression of functional molecules including sterile alpha motif domain-containing protein 9 (SAMD9), Ral guanine nucleotide dissociation stimulator-like 2 (RGL2), early growth response protein 1, and Akirin2. We also searched the BIOGPS database for protein expression profiles.

Results: SAMD9 and RGL2 expression levels were significantly upregulated in patients with pelvic pain. Furthermore, lysophosphatidic acid receptor 1 expression was higher in endometrial tissues from patients with pelvic pain, and was mainly localized in stromal and glandular epithelial cells in ectopic lesions.
**Conclusion:** NK cells play an important role in the pathogenesis of endometriosis in patients with pelvic pain. Suppressing the cytotoxic activity of NK cells may thus help to reduce the progression of pelvic pain in patients with endometriosis.

**Keywords**
NK cell, endometriosis, pelvic pain, sterile alpha motif domain-containing protein 9, Ral guanine nucleotide dissociation stimulator-like 2, lysophosphatidic acid receptor 1

Date received: 6 March 2019; accepted: 1 August 2019

**Introduction**
Endometriosis is a benign and often undetectable estrogen-dependent inflammatory disorder in women, leading to dysmenorrhea, pelvic pain, and infertility. Endometriosis is thought to affect around 10% to 15% of women of reproductive age.\(^1\) The etiology of endometriosis is complex, involving implantation, retrograde menstruation, coelomic metaplasia, and heredity.\(^2\) Clinically, endometriosis presents as three types: ovarian endometriosis, peritoneal endometriosis, and deep infiltrating endometriosis involving lesions deeper than 5 mm.\(^3\) However, this disease can remain asymptomatic, and there is still no accurate, easily accessible, and non-invasive method of diagnosis, and no effective drugs to overcome its complex pathologies. Immune reaction is one of the most widely accepted pathologies of endometriosis.\(^4\) Immune cells in the peritoneal cavity are stimulated by estrogen dysfunction, affecting T cell reactivity, activating B cells, increasing the number and activation of peritoneal macrophages, and regulating inflammatory mediators. Immune cells thus participate in clearing the refluxed endometrial tissues and modulating endometrial cell proliferation, and have a cytotoxic effect on endometrial cells via defensive natural killer (NK) cell activity.\(^5\)-\(^7\) M2 macrophages have been shown to play key roles in promoting endometriosis progression\(^8\) by modulating the implantation and proliferation of endometrial cells, while NK cells contribute to immunosurveillance via their cell surface activating and inhibitory receptors, such as NKG2-D type II integral membrane protein (NKG2D) and CD16 (FcγRIIIa).\(^9\) González-Foruria\(^10\) showed that reduced NK activity was a consequence of ectopic endometrial growth. Importantly, there is crosstalk among macrophages, NK cells, and T cells in the peritoneal microenvironment, and macrophages have been shown to modulate NK cell activity via derived cytokine morphs such as interleukin (IL)-6, IL-7, IL-15, and prostaglandins.\(^11,12\) NK T cells also contributed to the cytotoxic activities of the T-cell receptor-CD3 membrane complex and classical CD16, and via secreted cytokines such as IL-4 and IL-10.\(^13\) However, it is still not clear if these modulations of the immune response are a consequence of ectopic endometrial growth and the cause of dysmenorrhea, pelvic pain, and infertility in endometriosis. We therefore investigated the involvement of immune cells in the pathogenesis of endometriosis progression by analyzing blood samples from patients with stable disease and those with pelvic pain. A better understanding of the immunological dysfunctions occurring in endometriosis may clarify the pathogenesis of
the disease and contribute to the development of new clinical therapeutic strategies.

Materials and methods

Inclusion criteria

The inclusion criteria were patients aged between 18 and 40 years diagnosed at the First Affiliated Hospital of Anhui Medical University with endometriotic lesions in the peritoneal cavity, confirmed by peritoneoscope histological examination. Included patients had no autoimmune disease, confirmed by clinical data, physical examination, and laboratory tests, and had regular menstrual cycles once a month, or dysmenorrhea, pelvic pain, and infertility outcomes. Blood samples and endometrial tissues were collected from patients with stable status or with pelvic pain. Additionally, the study was approved by the Ethics Committee of The Seventh People’s Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, China (approval number: NO20180305). All patients provided written informed consent.

Clinical study

We collected blood samples (400 mL) from the included patients with and without pelvic pain. All blood samples for NK cell analysis were collected from patients with stable status or pelvic pain outside the menstrual period. Endometrial tissues were obtained by dilatation and curettage. The clinical samples from asymptomatic patients were considered as the control (‘stable’) group and samples from patients with pelvic pain as the experimental (‘pain’) group.

Enzyme-linked immunosorbent assays (ELISAs)

The collected blood samples were isolated three times by centrifugation at 1500 × g for 10 minutes each. The supernatants were then analyzed using ELISA kits for tumor necrosis factor (TNF)-α (catalog no: 70-EK182-96), IL-1β, (catalog no: 70-EK101B-96), IL-6 (catalog no: 70-EK106/2-96), IL-7 (catalog no: 70-EK107-96), IL-10 (catalog no: 70-EK110/2-96), and IL-15 (catalog no: 70-EK115-96) (all MultiSciences, China), according to the manufacturer’s instructions. All assays were carried out in triplicate.

Flow cytometry (FCM)

Monocytes were obtained from peripheral blood samples by Ficoll density-gradient centrifugation (Haoyang TBD Bio, Tianjin, China) and cultured in RPMI-1640 medium (Thermo, Beijing, China). CD3, CD56, CD4, IL-17, CD25, and Foxp3 expression were analyzed by FCM. The monocytes were fixed, permeabilized, and labeled with phycoerythrin-cyanine 7 (PE-Cy7)-conjugated anti-human CD56 antibody (catalog no: 25-0567-42), allophycocyanin (APC)-conjugated anti-human CD3 antibody (catalog no: 17-0038-42), PE-Cy7-conjugated anti-human CD4 antibody (catalog no: 25-0049-42), PE-conjugated anti-human IL-17 antibody (catalog no: 12-7517-42), PE-Cy7-conjugated anti-human CD25 antibody (catalog no: 25-0259-42), and APC-conjugated anti-human Foxp3 antibody (catalog no: 17-4777-42). All antibodies were from eBioscience (San Diego, CA, USA), and all protocols were carried out according to the manufacturer’s instructions. The cells were then washed twice and resuspended in phosphate-buffered saline for FCM analysis. Finally, the
samples were analyzed using a FACSCalibur (BD Bioscience, San Jose, CA, USA)

**Western blot**

Monocytes were obtained from peripheral blood samples by Ficoll density-gradient centrifugation (Haoyang TBD Bio) and lysed in 0.6 mL RIPA buffer (Beyotime) on ice for 20 minutes, followed by the addition of a protease inhibitor cocktail (phenylmethylsulfonyl fluoride, Beyotime). The protein samples were quantified using a bicinchoninic acid (Beyotime) assay and then separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to a polyvinylidene difluoride membrane (Bio-Rad, Hercules, CA, USA). The membranes were incubated in 5% nonfat milk for 1 hour and then incubated overnight at 4°C with primary antibodies to sterile alpha motif domain-containing protein 9 (SAMD9; catalog no: ab180575), Ral guanine nucleotide dissociation stimulator-like 2 (RGL2; catalog no: ab137600), early growth response protein 1EGR1 (catalog no: ab194357), and Akirin2 (catalog no: ab174805), respectively, (all Abcam, Cambridge, MA, USA), according to the manufacturer’s instructions. The membranes were then washed three times for 10 minutes each in TBST/1% Tween-20, and incubated with rabbit polyclonal antibody at 4°C for 60 minutes. An anti-glyceraldehyde 3-phosphatde dehydrogenase (GAPDH) monoclonal antibody (CST) was used as a control. Finally, the immunoreactive bands were visualized with an enhanced chemiluminescence detection instrument (Thermo Fisher Scientific, Rockford, IL, USA) with a chemiluminescent substrate. All procedures were performed according to the manufacturer’s instructions. Signals were analyzed using ImageJ 1.46 r (NIH, Bethesda, MD, USA) for statistical analysis.

**Immunohistochemistry**

Formalin-fixed, paraffin-embedded endometrial tissues obtained by laparoscopic hysterectomy from patients with stable disease or with pelvic pain were incubated with lysophosphatidic acid receptor 1 (LPAR1) antibody (catalog no: ab219601) and stained with 3,3'-diaminobenzidine (catalog no: 36201ES03; Yeasen, CA, USA). All procedures were performed according to the manufacturer’s instructions. Finally, the samples were visualized with a fluorescence microscope system (Leica, Solms, Germany).

**Statistical analysis**

The results were analyzed by Student’s t-tests and one-way analysis of variance (ANOVA) using SPSS for Windows, Version 19.0 (IBM Corp., Armonk, NY, USA). The results were considered statistically significant at \( P < 0.05 \).

**Results**

**Patients**

Forty-two patients were enrolled in this exploratory analysis (Table 1).

**NK cells were the predominant pathology of endometriosis in patients with pelvic pain**

Levels of the inflammatory cytokines TNF-\( \alpha \), IL-1\( \beta \), IL-6, and IL-7 were significantly upregulated in patients with pelvic pain compared with those with stable disease \( (P < 0.05) \) (Figure 1). The proportions of NK cells differed significantly between the two groups \( (P < 0.05) \), while those of Th17 and Treg cells did not (Figure 2). Furthermore, blood levels of SAMD9 and RGL2 were significantly higher in patients with pelvic pain compared with stable patients \( (P < 0.05) \) (Figure 3). These results
Table 1. Patient information.

| Patient no. | BMI  | Age | Endometriosis (yes/no) | Pelvic pain (yes/no) | Marital status (single/married/partnered/divorced) | Menstrual characteristics (age at menarche/cycle length/days of flow) | History of infertility (yes/no) | History of pregnancy | Current smoker | Family history (endometriosis/endometrial cancer) |
|-------------|------|-----|------------------------|----------------------|--------------------------------------------------|------------------------------------------------------------------|-----------------------------|---------------------|--------------|-----------------------------------------------|
| 1           | 18.1 | 26  | yes                    | yes                  | married                                         | 14/30/6                                                          | no                          | yes                 | no           | no                                            |
| 2           | 25.8 | 30  | yes                    | yes                  | married                                         | 13/27/7                                                         | no                          | yes                 | no           | no                                            |
| 3           | 20.9 | 31  | yes                    | yes                  | married                                         | 14/28/6                                                          | no                          | yes                 | no           | no                                            |
| 4           | 19.8 | 21  | yes                    | yes                  | married                                         | 12/28/6                                                          | no                          | yes                 | no           | no                                            |
| 5           | 21.5 | 25  | no                     | no                   | married                                         | 14/29/6                                                          | no                          | yes                 | no           | no                                            |
| 6           | 28.2 | 40  | yes                    | no                   | married                                         | 13/28/7                                                          | no                          | yes                 | no           | no                                            |
| 7           | 27.3 | 38  | no                     | no                   | married                                         | 12/28/7                                                          | no                          | yes                 | no           | no                                            |
| 8           | 25.3 | 35  | yes                    | no                   | married                                         | 14/29/6                                                          | no                          | yes                 | no           | no                                            |
| 9           | 23.1 | 25  | yes                    | yes                  | married                                         | 14/28/6                                                          | no                          | yes                 | no           | yes (endometriosis)                           |
| 10          | 22.6 | 43  | no                     | no                   | married                                         | 14/29/6                                                          | no                          | yes                 | no           | no                                            |
| 11          | 22.4 | 42  | yes                    | yes                  | married                                         | 14/28/6                                                          | no                          | yes                 | no           | no                                            |
| 12          | 28.9 | 27  | no                     | no                   | married                                         | 14/28/5                                                          | no                          | yes                 | no           | no                                            |
| 13          | 30.7 | 32  | yes                    | yes                  | divorced                                        | 14/28/7                                                          | no                          | yes                 | no           | no                                            |
| 14          | 29.9 | 41  | yes                    | no                   | married                                         | 14/28/6                                                          | no                          | yes                 | no           | no                                            |
| 15          | 25.1 | 28  | yes                    | yes                  | married                                         | 14/28/6                                                          | no                          | yes                 | no           | no                                            |
| 16          | 20.4 | 29  | yes                    | yes                  | married                                         | 14/28/6                                                          | no                          | yes                 | no           | no                                            |
| 17          | 21.6 | 36  | yes                    | yes                  | married                                         | 14/28/6                                                          | no                          | yes                 | no           | no                                            |
| 18          | 18.4 | 37  | no                     | no                   | married                                         | 14/28/6                                                          | no                          | yes                 | no           | no                                            |
| 19          | 19.3 | 35  | yes                    | no                   | married                                         | 14/28/6                                                          | no                          | yes                 | no           | yes (endometriosis)                           |
| 20          | 27.5 | 31  | yes                    | yes                  | married                                         | 14/30/6                                                          | no                          | yes                 | yes         | no                                            |
| 21          | 29.4 | 36  | yes                    | yes                  | married                                         | 14/28/6                                                          | no                          | yes                 | no           | no                                            |
| 22          | 30.8 | 37  | yes                    | no                   | married                                         | 14/29/6                                                          | no                          | yes                 | no           | no                                            |
| 23          | 27.9 | 40  | yes                    | yes                  | married                                         | 14/28/6                                                          | no                          | yes                 | no           | no                                            |
| 24          | 26.5 | 42  | yes                    | no                   | married                                         | 14/28/6                                                          | no                          | yes                 | no           | no                                            |
| 25          | 21.5 | 41  | yes                    | yes                  | married                                         | 14/28/6                                                          | no                          | yes                 | no           | yes (endometrial cancer)                     |

(continued)
| Patient no. | BMI   | Age | Endometriosis (yes/no) | Pelvic pain (yes/no) | Marital status (single/married/partnered/divorced) | Menstrual characteristics (age at menarche/cycle length/days of flow) | History of infertility (yes/no) | History of pregnancy | Current smoker | Family history (endometriosis/endometrial cancer) |
|------------|-------|-----|------------------------|----------------------|---------------------------------------------------|---------------------------------------------------------------------|-----------------------------|---------------------|---------------|-----------------------------------------------|
| 26         | 22.7  | 29  | yes                    | no                   | married                                           | 14/28/6                                                             | no                          | yes                 | no            | yes (endometrial cancer)                      |
| 27         | 23.8  | 28  | yes                    | yes                  | married                                           | 14/28/6                                                             | no                          | yes                 | no            | no                                            |
| 28         | 25.1  | 30  | yes                    | no                   | single                                            | 14/28/6                                                             | no                          | no                  | no            | no                                            |
| 29         | 21.6  | 31  | yes                    | no                   | married                                           | 14/28/6                                                             | no                          | yes                 | no            | no                                            |
| 30         | 23.2  | 27  | yes                    | no                   | single                                            | 14/30/7                                                             | no                          | no                  | no            | no                                            |
| 31         | 21.7  | 39  | yes                    | no                   | married                                           | 12/27/6                                                             | no                          | yes                 | no            | no                                            |
| 32         | 24.1  | 40  | yes                    | no                   | married                                           | 14/31/6                                                             | no                          | yes                 | no            | no                                            |
| 33         | 22.8  | 42  | yes                    | no                   | married                                           | 14/28/6                                                             | no                          | yes                 | no            | no                                            |
| 34         | 23.1  | 35  | yes                    | yes                  | married                                           | 13/28/6                                                             | no                          | yes                 | no            | yes (endometrial cancer)                      |
| 35         | 19.9  | 38  | yes                    | yes                  | married                                           | 12/28/6                                                             | yes                         | yes                 | no            | no                                            |
| 36         | 18.5  | 41  | yes                    | yes                  | married                                           | 12/30/6                                                             | no                          | yes                 | no            | yes (endometriosis)                           |
| 37         | 22.4  | 28  | yes                    | no                   | married                                           | 13/28/5                                                             | no                          | yes                 | no            | no                                            |
| 38         | 23.1  | 36  | yes                    | yes                  | married                                           | 14/28/7                                                             | no                          | yes                 | no            | no                                            |
| 39         | 26.6  | 25  | yes                    | no                   | married                                           | 12/28/6                                                             | no                          | yes                 | no            | no                                            |
| 40         | 23.3  | 43  | yes                    | yes                  | married                                           | 13/28/6                                                             | no                          | yes                 | no            | no                                            |
| 41         | 26.8  | 36  | yes                    | yes                  | married                                           | 12/28/6                                                             | no                          | yes                 | yes           | yes (endometriosis)                           |
| 42         | 29.3  | 38  | yes                    | no                   | married                                           | 13/28/6                                                             | no                          | yes                 | no            | no                                            |

BMI, body mass index
suggest that activated NK cells might have cytotoxic effects on endometrial and stromal cells during endometriosis progression, resulting in pelvic pain. We therefore concluded that NK cells represent the predominant pathology of endometriosis in patients with pelvic pain.

**LPAR1 expression in endometriotic lesions**

LPAR1 has been recognized to play roles in reorganization of the actin cytoskeleton, cell migration, differentiation, and proliferation, thereby contributing to the responses to tissue damage. LPAR could also mediate cytoplasmic Ca\(^{2+}\) levels through G protein-cellular cAMP signals. The current immunohistochemistry results revealed that LPAR1 was more abundant in endometriotic lesions in patients with pelvic pain than in patients with stable disease without pain (Figure 4). LPAR1 might thus play important roles in endometriotic lesions in patients with pelvic pain.

**Discussion**

The results of the current study based on clinical samples demonstrated a close involvement of immune cells in the pathogenesis of endometriosis progression. The proportion of NK cells in the peripheral blood was significantly higher in patients with endometriosis with pelvic pain compared with women with stable disease without pelvic pain. The proteins SAMD9 and RGL2 were also more highly expressed in blood samples from patients with pelvic pain, which were identified as being enriched in CD56\(^+\) NK cells by bioinformatics analysis. Furthermore, LPAR1 expression was increased in endometriotic lesions, as shown by immunohistochemistry. LPAR1 inhibits excessive degradation of the extracellular matrix facilitating the ectopic adhesion and growth of intimal cells, and inhibits the degradation of ectopic tissue and localization of the lesion. Promotion of blood vessel migration and growth provide the basis for the occurrence and development of endometriosis. We
therefore considered that NK cells were a predominant feature affecting the severity of endometriosis. In addition, the inflammatory cytokines TNF-α, IL-1β, IL-6, and IL-7 were also upregulated in patients with pelvic pain compared with those without pain, and we therefore speculated that other immune cells, such as macrophages, T lymphocytes, and dendritic cells\textsuperscript{14} might also participate in the immune battle during endometriosis progression. Gogacz et al.\textsuperscript{14} showed that increased percentages of Th17 cells in the peritoneal fluid and peripheral blood were associated with the severity of endometriosis. Furthermore, Tanaka et al.\textsuperscript{15} revealed that the dysregulated immune response of Treg cells contributed to the pathogenesis and development of endometriosis, while \textit{in vitro} and \textit{in vivo} experiments with models found that the secreted cytokines IL-10, transforming growth factor (TGF)-β, and IL-15 might downregulate the cytotoxicity of NK cells to trigger the immune escape of ectopic fragments and promote the occurrence and development of endometriosis.\textsuperscript{16,17}

\begin{figure}
\centering
\includegraphics[width=\textwidth]{fig2.png}
\caption{The proportions of NK cells differed significantly between the stable endometriosis and pain groups, whereas proportions of Th17 and Treg cells did not. (a, b) NK cells were activated and accumulated in the blood in patients with pelvic pain compared with patients with stable endometriosis ($^*P<0.05$), but there was little variation in Th17 (c, d) or Treg cells (e, f) between the two groups.}
\end{figure}
The chemokines CCL19/CCR7 and fractalkine/CX3CR1 were separately identified as contributing to the pathogenesis of endometriosis.\textsuperscript{18,19} Increasing numbers of studies have suggested that endometriosis is driven by endocrine-immune-inflammatory reactions in the inner microenvironment.\textsuperscript{20} Zhu et al.\textsuperscript{21} showed that estrogen might be a key factor in the degranulation and recruitment of mast cells, leading to endometriosis-associated dysmenorrhea. Burns et al.\textsuperscript{22} suggested that endometriosis comprised two phases, an immune dependent phase and a hormone-dependent phase, with the predominant phase depending on estrogen/estrogen receptor α/IL-6-mediated crosstalk. Furthermore, signals from the endometrial tissues also affected the immune function; for example, CD200 from endometrial venules could promote Tregs and indoleamine 2,3-dioxygenase-producing macrophages, and inhibit cytolytic NK cells and neutrophils in the pathology of endometriosis progression.\textsuperscript{23} Thrombin and thromboxane A2 secreted from stromal cells\textsuperscript{24} could induce platelet activation, and the activated platelets then mediated NK cytotoxicity through

**Figure 3.** Expression levels of SAMD9, RGL2, EGR1, and Akirin2 were analyzed in monocytes by western blot. (a) SAMD9 and RGL2 proteins were highly expressed in blood from patients with pelvic pain compared with stable patients. (b) *$P<0.05$ between the stable and corresponding pain groups.

**Figure 4.** Expression levels of LPAR1 in endometriotic tissues in patients with stable disease and pelvic pain, detected by immunohistochemistry ($\times200$). (a) LPAR1 was more abundant in endometriotic tissue from patients with pelvic pain. (b) *$P<0.05$.
NKG2D and TGF-β signals during endometriosis progression.²⁵,²⁶ It is therefore possible that activated NK cells may cooperate with other immune cells in their interactions with stromal cells and platelets in endometriosis progression. Further in vitro and in vivo experiments with models are needed to clarify the pathology of endometriosis, and to determine if the immune response is modulated as a consequence of ectopic endometrial growth and is the cause of dysmenorrhea, pelvic pain, and infertility in patients with endometriosis.

Declaration of conflicting interest

The authors declare that there is no conflict of interest.

Funding

This research was supported by project funding from the Shanghai TCM Academic Experience Research Studio (SHGZS-2017002).

References

1. Han SJ and O’Malley BW. The dynamics of nuclear receptors and nuclear receptor coregulators in the pathogenesis of endometriosis. *Hum Reprod Update* 2014; 20: 467–484.
2. Mate G, Bernstein LR and Torok AL. Endometriosis is a cause of infertility. Does reactive oxygen damage to gametes and embryos play a key role in the pathogenesis of infertility caused by endometriosis? *Front Endocrinol (Lausanne)* 2018; 9: 725.
3. Tosti C, Pinzauti S, Santulli P, et al. Pathogenetic mechanisms of deep infiltrating endometriosis. *Reprod Sci* 2015; 22: 1053–1059.
4. Izumi G, Koga K, Takamura M, et al. Involvement of immune cells in the pathogenesis of endometriosis. *J Obstet Gynaecol Res* 2018; 44: 191–198.
5. Riccio L, Santulli P, Marcellin L, et al. Immunology of endometriosis. *Best Pract Res Clin Obstet Gynaecol* 2018; 50: 39–49.
6. Matsuoka S, Maeda N, Izumiya C, et al. Expression of inhibitory-motif killer immunoglobulin-like receptor, KIR2DL1, is increased in natural killer cells from women with pelvic endometriosis. *Am J Reprod Immunol* 2005; 53: 249–254.
7. Kralickova M, Fiala L, Losan P, et al. Altered immunity in endometriosis: what came first? *Immunol Invest* 2018; 47: 569–582.
8. Cominelli A, Gaide Chevonnay HP, Lemoine P, et al. Matrix metalloproteinase-2 is expressed in CD163+/CD206+ M2 macrophages in the cycling human endometrium and in superficial endometriotic lesions. *Mol Hum Reprod* 2014; 20: 767–775.
9. Funamizu A, Fukui A, Kamoi M, et al. Expression of natural cytotoxicity receptors on peritoneal fluid natural killer cell and cytokine production by peritoneal fluid natural killer cell in women with endometriosis. *Am J Reprod Immunol* 2014; 71: 359–367.
10. González-Foruria I, Santulli P, Chouzenoux S, et al. Soluble ligands for the NKG2D receptor are released during endometriosis and correlate with disease severity. *PLoS One* 2015; 10: e0119961.
11. Bellelis P, Frediani Barbeiro D, Gueuvoghlian-Silva BY, et al. Interleukin-15 and interleukin-7 are the major cytokines to maintain endometriosis. *Gynecol Obstet Invest* 2019; 5: 1–10.
12. Bellelis P, Barbeiro DF, Rizzo LV, et al. Transcriptional changes in the expression of chemokines related to natural killer and T-regulatory cells in patients with deep infiltrative endometriosis. *Fertil Steril* 2013; 99: 1987–1993.
13. Osuga Y, Koga K, Hirota Y, et al. Lymphocytes in endometriosis. *Am J Reprod Immunol* 2011; 65: 1–10.
14. Gogacz M, Winkler I, Bojarska-Junak A, et al. Increased percentage of Th17 cells in peritoneal fluid is associated with severity of endometriosis. *J Reprod Immunol* 2016; 117: 39–44.
15. Tanaka Y, Mori T, Ito F, et al. Exacerbation of endometriosis due to regulatory T-cell dysfunction. *J Clin Endocrinol Metab* 2017; 102: 3206–3217.
16. Yang HL, Zhou WJ, Chang KK, et al. The crosstalk between endometrial stromal cells and macrophages impairs cytotoxicity of
NK cells in endometriosis by secreting IL-10 and TGF-beta. *Reproduction* 2017; 154: 815–825.

17. Yu JJ, Sun HT, Zhang ZF, et al. IL-15 promotes growth and invasion of endometrial stromal cells and inhibits killing activity of NK cells in endometriosis. *Reproduction* 2016; 152: 151–160.

18. Diao R, Wei W, Zhao J, et al. CCL19/CCR7 contributes to the pathogenesis of endometriosis via PI3K/Akt pathway by regulating the proliferation and invasion of ESCs. *Am J Reprod Immunol* 2017; 78: e12744.

19. Hou XX, Hou WJ, Wang XQ, et al. Fractalkine/CX3CR1 is involved in the pathogenesis of endometriosis by regulating endometrial stromal cell proliferation and invasion. *Am J Reprod Immunol* 2016; 76: 318–325.

20. Grandi G, Mueller MD, Papadia A, et al. Inflammation influences steroid hormone receptors targeted by progestins in endometrial stromal cells from women with endometriosis. *J Reprod Immunol* 2016; 117: 30–38.

21. Zhu TH, Ding SJ, Li TT, et al. Estrogen is an important mediator of mast cell activation in ovarian 2 endometriomas. *Reproduction* 2017; 155: 73–83.

22. Burns KA, Thomas SY, Hamilton KJ, et al. Early endometriosis in females is directed by immune-mediated estrogen receptor alpha and IL-6 cross-talk. *Endocrinology* 2018; 159: 103–118.

23. Clark DA, Dmetrichuk JM, Dhesy-Thind S, et al. Soluble CD200 in secretory phase endometriosis endometrial venules may explain endometriosis pathophysiology and provide a novel treatment target. *J Reprod Immunol* 2018; 129: 59–67.

24. Guo SW, Du Y and Liu X. Endometriosis-derived stromal cells secrete thrombin and thromboxane A2, inducing platelet activation. *Reprod Sci* 2016; 23: 1044–1052.

25. Guo SW, Du Y and Liu X. Platelet-derived TGF-beta1 mediates the down-modulation of NKG2D expression and may be responsible for impaired natural killer (NK) cytotoxicity in women with endometriosis. *Hum Reprod* 2016; 31: 1462–1474.

26. Du Y, Liu X and Guo SW. Platelets impair natural killer cell reactivity and function in endometriosis through multiple mechanisms. *Hum Reprod* 2017; 32: 794–810.